“Despite concerns that large, rapid weight losses could precipitate disordered eating and psychosocial complications, semaglutide, relative to placebo, showed larger improvements in several measures of disordered eating and body image concern,” said Kelly C. Allison, PhD, professor of psychiatry at the Perelman School of Medicine, University of Pennsylvania, during a presentation at ObesityWeek 2026.
The finding comes from a secondary analysis of a randomized, placebo-controlled trial published Nov. 15 in the International Journal of Eating Disorders. Researchers assigned 120 adults with obesity to semaglutide 2.4 mg or placebo, both with lifestyle counseling, for 60 weeks. Participants completed validated eating behavior questionnaires at baseline and weeks 20, 40, and 60.
At baseline, 6.9% of the semaglutide group and 12.5% of the placebo group met criteria for binge eating disorder (BED), while 22.2% and 31.3%, respectively, reported any binge episodes in the prior 12 weeks. Among the 18 participants with full or subthreshold BED, none of the eight in the semaglutide arm had BED at weeks 20 or 40, and 88% maintained remission at week 60, compared with 50% in the placebo arm at weeks 20 and 40 and 75% at week 60, Medscape reported.
Among 31 participants reporting baseline binge episodes, those on semaglutide were 45 to 51 percentage points more likely than placebo to have no objective or subjective binge episodes at weeks 40 and 60. No significant differences emerged in binge frequency between groups over the full 60 weeks.
At all three assessment points, the semaglutide group showed significantly greater reductions than placebo on the Eating Disorder Inventory Global Score, Loss of Control Over Eating Scale, uncontrolled eating, and emotional eating (P < .05). Scores for drive for thinness, body dissatisfaction, and weight concern also fell more sharply with semaglutide.
“Our findings suggest that semaglutide not only supports weight loss but may also improve several measures of eating disorder psychopathology and loss of control eating in many patients,” said Jena Tronieri, PhD, senior research investigator at Penn’s Center for Weight and Eating Disorders, in a Newswise release.
New-onset binge eating appeared numerically higher with placebo — 18.5% versus 9.6% at week 60 among those reporting any binge episodes — but the 3:2 randomization and higher placebo dropout (43.7% vs 15.3%) made estimates unreliable. “The true numbers really are unknown…. You can see though, that the rates are quite low, fortunately,” Allison told Medscape.
No participant reported laxative or diuretic use. One semaglutide recipient with a past history of occasional vomiting reported four episodes of intentional vomiting alongside increased drive for thinness and dietary restraint scores. Two others in the semaglutide group reported excessive exercise. Overall, seven participants with a history of bulimia nervosa and 12 with a history of inappropriate compensatory behaviors reported no such behaviors or binge episodes at any assessment.
Session moderator Amin Sabet, MD, endocrinologist and obesity medicine specialist at UMass Chan Medical School, called the data “excellent” and reassuring but flagged a key limitation.
“We don’t know specifically how many people had a restrictive eating disorder at baseline or developed one during treatment…. How do we identify people with existing or a history of restrictive eating disorders, which I think are not rare and more risky when we’re using these drugs?” Sabet told Medscape.
Allison noted a soon-to-be-published validated tool, Screening Kids’ and Teens’ Eating, designed to differentiate food restriction due to GLP-1–related appetite suppression from an eating disorder. “So I would say be on the lookout for that,” she advised.
The findings align with recently published consensus recommendations co-authored by Allison, which advise screening all individuals for current or prior eating disorders before initiating a GLP-1 receptor agonist.
Allison told Medscape clinicians “should feel comfortable asking people how their eating is going in a broad open way…people with restrictive eating disorders sometimes want to keep those behaviors to themselves but I think providers do need to be aware that this could be an issue.”
The trial was supported by Novo Nordisk through an investigator-sponsored research grant to the University of Pennsylvania. Allison disclosed investigator-sponsored funding from Novo Nordisk on behalf of Penn. Sabet reported equity holdings in Abbott, AbbVie, Eli Lilly, Johnson & Johnson, Merck, and Novo Nordisk.
The study’s primary outcomes — energy intake, appetite, and food reward — were published separately; this analysis focused exclusively on eating disorder psychopathology and body image measures collected at the same visits.
New-onset binge eating and compensatory behaviors were rare in both groups. Rates appeared numerically higher with placebo, but dropout and randomization ratios prevented firm conclusions.
The data suggest the opposite: participants with baseline binge episodes were more likely to achieve remission on semaglutide than placebo. Current guidelines recommend screening and monitoring, not exclusion.
Allison, who directs the Center for Weight and Eating Disorders at the Perelman School of Medicine, led a 2022 pilot randomized trial of liraglutide 3.0 mg for binge eating disorder.
She earned her B.A. from the University of Notre Dame and her M.A. and Ph.D. from Miami University and has published more than 185 peer-reviewed papers and chapters along with two books. Her research spans night eating syndrome, the timing of eating, bariatric surgery outcomes, and the interplay of weight and eating behaviors on women’s health.
The trial did not report how many participants had restrictive eating disorders at baseline or developed them during treatment. Experts say this remains an open question and a validated screening tool is forthcoming.
Related reading